



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,900	11/13/2003	Mahmoud M. Abdel-Monem	P05844US02	7757

22885 7590 12/28/2005

MCKEE, VOORHEES & SEASE, P.L.C.
801 GRAND AVENUE
SUITE 3200
DES MOINES, IA 50309-2721

EXAMINER

OH, TAYLOR V

ART UNIT	PAPER NUMBER
----------	--------------

1625

DATE MAILED: 12/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/706,900	Applicant(s) ABDEL-MONEM ET AL.	
	Examiner Taylor Victor Oh	Art Unit 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 October 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Final Rejection

The Status of Claims

Claim 1 is pending.

Claim 1 has been rejected.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The rejection of Claim 1 under 35 U.S.C. 112, second paragraph has been withdrawn due to the modification of the claim.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of Claims 1-2 under 35 U.S.C. 112, first paragraph, has been withdrawn.

Newly Applied Rejection

Because applicants have newly revised claim 1 in the amendment, the prior art rejection are applied.

Claim Rejections - 35 USC § 103

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

Art Unit: 1625

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

1. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Moore (US 6,323, 354).

Moore teaches that a method for preparing amino acid transition metal chelates as a palatable highly bioavailable source for transition metals for animal nutrition from lipoproteins comprising nucleoprotein , nucleic acids ,keratins, collagen , and glutamic acid (see col. 8 ,lines 29-33) and transition metal salts selected from the group consisting of iron, zinc, copper, magnesium , and etc. (see col. 4 , lines 55-58).

The product of Example 1, containing 9.55 weight percent zinc was fed at a rate of 1.8 grams of product per head per day to feedlot beef cattle with no sign of feed rejections. A still higher feed rate of 4.0 grams of product was fed to a lactating dairy herd with good palatability of the feed containing the chelate product observed.

(see col. 7 ,lines

1-6).

The instant invention, however, differs from the prior art in that the 1:1 neutral complex of an essential trace element and a dicarboxylic alpha amino acid is recited.

Even so, the reference does offer the following guidance for how to prepare amino acid transition metal chelates in the 1:1 neutral complex between them (see col. 3 ,lines 17-25):

To effectively form the chelate, it is necessary to neutralize the aqueous sodium or potassium salts of the amino acids and fatty acids to a pH between 3 and 7. Then, the water soluble salts of transition metals may be reacted with the neutralized sodium or potassium salts of amino acids and fatty acids to provide between 1 and 3, and preferably between 1.8 and 2.5 molecules of amino acid per transition metal, thereby forming an aqueous mixture of amino acid transition metal chelates and fatty acids.

From this teaching, it is possible for the skilled artisan in the art to prepare the 1:1 neutral complex of the Fe element (see col. 4 , line 57) and the glutamic acid (see col. 8 ,line 33) because Moore expressly teaches the broad workable range of from 1 to 3 molecules of amino acid per transition metal. Therefore, it would have been obvious to the skilled artisan in the art to be motivated to change from the prior art ratio to the claimed ratio by routine experimentation depending upon the weight of the animal by routine experimentation. This is because such a modification to be successful and feasible as the guidance (see col. 3 ,lines 17-25) shown in the prior art.

2. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over ICN (A world of Biomemddical Products Catalogue, 1995, p. 1194).

ICN teaches a synthetic amino diet mixture for an animal comprising L-aspartic acid (0.34 %) , L-glutamic acid (3.41 %) , salt mixture containing magnesium salt (9.98 %), copper

Art Unit: 1625

salt (0.15%), zinc salt (0.02 %), iron salt (0.62 %), and etc. (see page 1194, right column).

Furthermore, the prior art has offered guidance that the composition can be adjusted to pellet by adding dextrin and sucrose ingredients (see page 1194, right column).

The instant invention, however, differs from the prior art in that the 1:1 neutral complex of an essential trace element and a dicarboxylic alpha amino acid is recited.

Even so, the reference does offer the guidance that the synthetic amino diet composition can be adjusted depending on its use(see page 1194, right column). Furthermore, it is well-established that merely selecting proportions and ranges is not patentable absent a showing of criticality . In re Becker, 33 USPQ 33 (C.C.P.A. 1937). In re Russell, 439 F. 2d 1228, 169 USPQ 426 (C.C.P.A.). Therefore, it would have been obvious to the skilled artisan in the art to be motivated to change from the prior art ratio to the claimed ratio depending upon the use of the amino acid diet for any particular animal. This is because such a modification to be successful and feasible as the guidance (see page 1194, right column) shown in the prior art.

Applicants' Argument

Art Unit: 1625

I. Applicants argue the following issues:

- a. The terms referred to “a 1:1 neutral complex of an essential trace element and a dicarboxylic alpha amino acid” present in the animal and human is far from being ambiguous since it is established by regulatory agencies and scientific communities; therefore, it is definite for those terms.
- b. The phrase “an essential trace element” ... to an animal is enabled since it is impossible to accurately present the requirement of all essential trace elements in the context of a claim in a patent application.

The applicants' argument have been noted, but these arguments are not persuasive.

First, with respect to the first argument, the Examiner has withdrawn the rejection of Claim 1 under 35 U.S.C. 112, second paragraph because the claim has been modified from “a 1:1 neutral complex of an essential trace element and a dicarboxylic alpha amino acid” to “a neutral complex of an essential trace element and a dicarboxylic alpha amino acid, containing one ion of the trace element for each molecule of the dicarboxylic amino acid”.

Second, with respect to the second argument, the Examiner has withdrawn the rejection of Claim 1 under 35 U.S.C. 112, first paragraph, not because the phrase “an essential trace element” ... to an animal is enabled, but because there are no terms “to an animal” present in claim 1.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


12/20/05


Cecilia J. Tsang
Supervisory Patent Examiner
Technology Center 1600